ArticleAutoimmunity2011
Leptin treatment confers clinical benefit at multiple stages of virally induced type 1 diabetes in BB rats.
Article in Autoimmunity, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.Journal of diabetes science and technology · 2014Trial
- Review
- Development of the Nonobese Diabetic Mouse and Contribution of Animal Models for Understanding Type 1 Diabetes.Pancreas · 2017Review
- Is a β cell a β cell?Current opinion in endocrinology, diabetes, and obesity · 2017Review
- The role of autonomic efferents and uncoupling protein 1 in the glucose-lowering effect of leptin therapy.Molecular metabolism · 2016Article
- Skeletal muscle as a therapeutic target for delaying type 1 diabetic complications.World journal of diabetes · 2015Review
- Insulin-independent reversal of type 1 diabetes in nonobese diabetic mice with brown adipose tissue transplant.American journal of physiology. Endocrinology and metabolism · 2015Article
- Benefits of healthy adipose tissue in the treatment of diabetes.World journal of diabetes · 2014Review
- Factors determining insulin requirements in women with type 1 diabetes mellitus during pregnancy: a review.Obstetric medicine · 2014Review
- Pathological endoplasmic reticulum stress mediated by the IRE1 pathway contributes to pre-insulitic beta cell apoptosis in a virus-induced rat model of type 1 diabetes.Diabetologia · 2013Article
- Review
- Review
- Article
- Adipose tissue, hormones, and treatment of type 1 diabetes.Current diabetes reports · 2012Review
- Autoimmunity in 2011.Clinical reviews in allergy & immunology · 2012Review
- The role of leptin in glucose homeostasis.Journal of diabetes investigation · 2012Review
- Expanding neurotransmitters in the hypothalamic neurocircuitry for energy balance regulation.Protein & cell · 2011Review
- Leptin therapy reverses hyperglycemia in mice with streptozotocin-induced diabetes, independent of hepatic leptin signaling.Diabetes · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
The adipokine, leptin, regulates blood glucose and the insulin secretory function of beta cells, while also modulating immune cell function. We hypothesized that the dual effects of leptin may prevent or suppress the autoreactive destruction of beta cells in a virally induced rodent model of type 1 diabetes. Nearly 100% of weanling BBDR rats treated with the combination of an innate immune system activator, polyinosinic:polycytidylic acid (pIC), and Kilham rat virus (KRV) become diabetic within a predictable time frame. We utilized this model to test the efficacy of leptin in preventing diabetes onset, remitting new onset disease, and preventing autoimmune recurrence in diabetic rats transplanted with syngeneic islet grafts. High doses of leptin delivered via an adenovirus vector (AdLeptin) or alzet pump prevented diabetes in>90% of rats treated with pIC+KRV. The serum hyperleptinemia generated by this treatment was associated with decreased body weight, decreased non-fasting serum insulin levels, and lack of islet insulitis in leptin-treated rats. In new onset diabetics, hyperleptinemia prevented rapid weight loss and diabetic ketoacidosis, and temporarily restored euglycemia. Leptin treatment also prolonged the survival of syngeneic islets transplanted into diabetic BBDR rats. In diverse therapeutic settings, we found leptin treatment to have significant beneficial effects in modulating virally induced diabetes. These findings merit further evaluation of leptin as a potential adjunct therapeutic agent for treatment of human type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.